CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
The company is moving towards complex and more differentiated products
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Nelarabine is in a class of medications called antimetabolites
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
The company performed particularly well in operational eco-efficiency, environmental and social reporting
The centre has an initial capacity of 500 FTEs
Subscribe To Our Newsletter & Stay Updated
